Inhaler article

Abstract

The present invention relates to an inhaler article. An inhaler article includes a tubular body. The tubular body includes an inner airflow channel extending between a mouth end of the tubular body and a distal end of the tubular body. An inhaler article includes a cavity for receiving an aerosol-forming substrate. A lumen is disposed in the tubular body between the mouth end and the distal end. The inhaler article includes a resealable retention element disposed at a location distal to the lumen. The resealable retention element is configured to be switchable between an open position and a closed position. In the open position, the distal end of the tubular body is fluidly connected to the lumen. In the closed position, the distal end of the tubular body is fluidly isolated from the lumen. The invention also relates to an inhaler system comprising an inhaler article and a holder.

Description

TECHNICAL FIELD

[0001] The present invention relates to an inhaler article. The present invention also relates to an inhaler system comprising an inhaler article and a holder. BACKGROUND

[0002] Inhaler articles are known, for example dry powder inhalers. Certain inhaler articles hold capsules containing dry powder. These capsules can be activated by piercing the capsule wall. The active substance of the dry powder can then be entrained by an airflow through the inhaler article and can be delivered to the mouth of a user for inhalation. After use, powder residue in the inhaler article can inadvertently leak out of the distal end of the article. SUMMARY

[0003] It is desirable to provide an inhaler article that reduces or avoids leakage. It is desirable to provide an inhaler system that can be comfortably handheld by a user.

[0004] According to embodiments of the present invention, there is provided an inhaler article. The inhaler article can comprise a tubular body. The tubular body can comprise an internal airflow passage extending between a mouth end of the tubular body and a distal end of the tubular body. The inhaler article can comprise a cavity for receiving an aerosol-forming substrate. The cavity can be disposed in the tubular body between the mouth end and the distal end. The inhaler article can comprise a resealable trap element disposed at a location distal of the cavity. The resealable trap element can be configured to be switchable between an open position and a closed position. In the open position, the distal end of the tubular body can be fluidly connected to the cavity. In the closed position, the distal end of the tubular body can be fluidly isolated from the cavity.

[0005] According to embodiments of the present invention, there is provided an inhaler article. The inhaler article comprises a tubular body. The tubular body comprises an internal airflow passage extending between a mouth end of the tubular body and a distal end of the tubular body. The inhaler article comprises a cavity for receiving an aerosol-forming substrate. The cavity is disposed in the tubular body between the mouth end and the distal end. The inhaler article comprises a resealable trap element disposed at a location distal of the cavity. The resealable trap element is configured to be switchable between an open position and a closed position. In the open position, the distal end of the tubular body is fluidly connected to the cavity. In the closed position, the distal end of the tubular body is fluidly isolated from the cavity.

[0006] The resealable trap element can be configured to switch between the open position and the closed position in dependence on the presence or absence of a pressure differential in the internal airflow passage generated between the mouth end and the distal end of the tubular body.

[0007] The ability of the resealable trapping element to switch between an open position and a closed position based on a pressure differential within the internal airflow channel can bring several advantages. It can ensure effective airflow control. It can prevent leakage when the inhaler is not in use. It can facilitate cleanliness. Overall, it can improve one or more of user experience, dose accuracy, and device reliability.

[0008] The resealable trapping element can be configured to move towards the open position when a negative pressure is applied at the mouth end. The resealable trapping element can be configured to move back towards the closed position in the absence of a negative pressure. This can ensure optimal drug delivery. As the negative pressure subsides, the element can revert to the closed position, thereby minimising any potential loss.

[0009] As used herein, the term "negative pressure" refers to a condition in which the pressure of a fluid or gas is lower than the atmospheric pressure of its surroundings. In other words, it is a state in which the pressure within a confined space is less than the pressure outside of that space. Negative pressure can cause a fluid or gas to be drawn from an area of high pressure into an area of low pressure, resulting in a pulling or suction effect.

[0010] The resealable trapping element can comprise a flexible portion. The flexible portion can be movable between a relaxed configuration when the resealable trapping element is in the closed position and a tensioned configuration when the resealable trapping element is in the open position.

[0011] As used herein, the term "flexible portion" refers to a particular segment or portion of an object or material that is capable of bending, moving, or changing shape without breaking or losing its structural integrity. This flexibility can allow the portion to adapt to different positions or conditions while returning to its original form upon removal of the external force causing the bending.

[0012] In its closed configuration, the flexible portion can be in a relaxed state. Conversely, when the resealable trapping element transitions to an open configuration, the flexible portion can switch into a tensioned configuration. This can provide a controlled and intentional manipulation between different positions. This mechanism can contribute to the efficacy of the element, enabling it to seamlessly establish a secure seal when in the closed state and facilitating unobstructed airflow when in the open state.

[0013] The resealable trapping element can be configured as a disc. The disc can have a cylindrical shape. The disc's cylindrical axis can be arranged to coincide with the longitudinal central axis of the inhaler article. The disc can have a right cylindrical shape. The right cylinder can be a flat cylinder. As used herein, the term "flat cylinder" refers to a cylinder whose diameter exceeds the height of the cylinder along the cylinder axis. The disc-shaped resealable trapping element can have a diameter between 5 millimetres and 13 millimetres, preferably between 6 millimetres and 11 millimetres, more preferably between 7 millimetres and 9 millimetres. The disc-shaped resealable trapping element can have a height between 0.1 millimetres and 4 millimetres, preferably between 0.1 millimetres and 3 millimetres, more preferably between 0.1 millimetres and 2 millimetres.

[0014] The resealable trapping element can comprise one or more lines of weakness. The one or more lines of weakness can provide the resealable trapping element with one or more flexible flaps. The flexible portion can be provided by the one or more flexible flaps of the resealable trapping element.

[0015] The one or more flexible flaps can collectively constitute the flexible portion of the resealable trapping element. The incorporation of these flaps through lines of weakness can impart the necessary adaptability of the resealable trapping element to its modes of operation.

[0016] The one or more lines of weakness can be lines of perforation. The one or more lines of weakness can be lines of cut.

[0017] The resealable trapping element can comprise two lines of weakness arranged orthogonally to provide four flexible flaps of equal size. The resealable trapping element can comprise two lines of cut arranged orthogonally to provide four flexible flaps of equal size.

[0018] The resealable trapping element can be a disc and can comprise two lines of weakness arranged orthogonally to provide four flexible flaps of equal size. The resealable trapping element can be a disc and can comprise two lines of cut arranged orthogonally to provide four flexible flaps of equal size.

[0019] The lines of weakness can be used to create four flexible flaps of equal size. This arrangement can ensure a balanced distribution of flexibility across the structure of the disc. This arrangement can optimize responsiveness and adaptability during transitions between operational states.

[0020] The resealable trapping element can comprise a one-way valve. The one-way valve can comprise a valve flap that is movable between a closed position and an open position. This mechanism can enable one-way airflow control. This mechanism can allow inhalation while preventing exhalation or backflow. The mobility of the valve flap can facilitate its transition from the closed position to the open position. This can ensure seamless and controlled inhalation.

[0021] The inhaler article can comprise a distal end. The inhaler article can comprise a proximal end opposite the distal end. The proximal end can be a mouth end. The proximal end can comprise a mouthpiece.

[0022] Inhaler articles may include a front bar. The front bar may be positioned at or near the distal end of the inhaler article. The term "front bar" may also be referred to as "end bar". The terms "front bar" and "end bar" are used synonymously herein.

[0023] The front bar can be positioned at the distal end of the tubular body. The front bar can be positioned at the distal end of the inhaler article. The front bar can be a flanged front bar.

[0024] Inhaler articles may include a flanged front bar disposed at the distal end of a tubular body. The distal end of the tubular body may be at least partially closed by the flanged front bar. The terms "flared front bar" and "flared end bar" are used synonymously herein.

[0025] The resealable trap element can be attached to the flanged front bar.

[0026] The resealable trap element can be attached to the inner side of the flanged front bar.

[0027] The flanged front bar can be used to partially or completely close the distal end of the tubular body. This arrangement facilitates controlled airflow management, enhances the inhalation process, and promotes efficient delivery of the active ingredient to the user.

[0028] The resealable trap element can be attached to the outer side of the flanged front bar. This arrangement optimizes space utilization while maintaining the functionality of the element. By being located on the outside of the bar, the trap element remains easily accessible for operation while still effectively contributing to the overall design and airflow control of the inhaler article.

[0029] The resealable retaining element can be attached to the distal end of the tubular body via a connecting package. The connecting package facilitates a secure and reliable connection between the element and the tubular body. This ensures proper positioning and functionality of the retaining element.

[0030] The connecting packaging can be a paper outer packaging. This type of packaging provides a practical and readily available means of securing the resealable retention element to the distal end of the tubular body. The use of a paper outer packaging ensures a functional and user-friendly connection while maintaining an overall aesthetic appeal within the design of the inhaler article.

[0031] Inhaler articles may include a retention rod. The retention rod may be positioned between the lumen and the proximal end. The retention rod may be spatially positioned between the lumen and the proximal end. The retention rod may be spatially positioned between the lumen and the proximal end along the longitudinal axis of the inhaler article.

[0032] This placement can be used to separate the cavity from the proximal end, thereby creating a barrier within the inhaler article. This configuration can facilitate controlled movement of substances within the device and can enhance the overall functionality of the inhaler article.

[0033] Retention rods may include bioplastics. The use of bioplastics may align with environmental principles and provide a sustainable option for the construction of retention rods. The use of bioplastics can help reduce environmental impact and promote the adoption of environmentally friendly alternatives in the design of inhaler products. As used herein, the term "bioplastic" refers to a plastic material derived from renewable biological sources such as plants, algae, or other organic materials. Unlike conventional plastics derived from fossil fuels, bioplastics utilize supplemental natural feedstocks, thereby reducing dependence on non-renewable resources and mitigating the environmental impact associated with conventional plastic production.

[0034] The resealable trapping element may contain at least one of tobacco, cotton, paper, rayon, cork, latex, starch-based plastic material, and silicone.

[0035] Resealable retention elements can potentially be incorporated into any of the following materials: tobacco, cotton, paper, rayon, cork, latex, starch-based plastics, or silicone. These materials offer a range of options to suit different functional and design requirements of the retention element. Each material choice can bring its unique properties, thus contributing to the overall performance and versatility of the element within an inhaler article.

[0036] The tubular body may include cardboard. This material choice offers a combination of structural integrity and recyclability, making it a suitable option for forming the body of an inhaler article. The use of cardboard may align with sustainable practices. The use of cardboard can provide the device with a lightweight yet durable structure.

[0037] The cavity may include an aerosol-forming matrix.

[0038] The cavity can be a capsule configured to receive a sac comprising an aerosol-forming matrix. The cavity may include a sac. The cavity may include a sac containing an aerosol-forming matrix. The aerosol-forming matrix may be provided in the form of particles as described herein. The aerosol-forming matrix may be a powder. The aerosol-forming matrix may be a dry powder.

[0039] A cavity is a capsule that ensures that the inhaler article is customized to hold a specific aerosol-forming matrix capsule and facilitates the delivery of that specific aerosol-forming matrix capsule. It can optimize the compatibility between the inhaler article and the intended aerosol-forming matrix delivery mechanism.

[0040] The capsule may be a puncturable capsule. A puncturable capsule may include pharmaceutically active particles. A puncturable capsule may include pharmaceutically active particles in the form of a dry powder. The pharmaceutically active particles may contain nicotine. As used herein, the term "aerosol-forming matrix" also covers dry powders known for use in dry powder inhalers.

[0041] The puncturable capsule can contain pharmaceutically active particles in the form of a dry powder. Optionally, these particles may contain nicotine. This configuration can be particularly well-suited for delivering pharmaceutically active particles by inhalation, thereby allowing for effective and targeted administration.

[0042] The resealable trap element can be a sponge-like or foam-like element. The sponge-like or foam-like element can include sponge-like or foam-like materials. The sponge-like or foam-like materials can be any type of sponge known to those skilled in the art. For example, polymeric sponges, cellulose-based sponges, synthetic sponges, or any combination thereof. Cellulose-based sponges can advantageously be completely sustainable.

[0043] The density of the sponge-like or foam-like element and the elasticity of its constituent materials can limit the effectiveness of the element in opening and closing within and after removal from the retainer. According to specific embodiments, the thickness of the sponge-like or foam-like element can be varied to optimize sealing efficiency and effectiveness. For example, reducing the thickness can reduce the force required for insertion, and vice versa.

[0044] The sponge-like or foam-like element may include one or more weakening lines. The weakening lines of the sponge-like or foam-like element may be configured as cutting lines. Various cutting shapes are possible. By changing the cutting shape, the opening and closing behavior of the element in and after being removed from the retainer can be varied. For example, when the number of cutting lines is increased, the force required for insertion can be reduced. By changing the cutting shape, the sponge-like or foam-like element can therefore be optimized according to the requirements of a particular embodiment.

[0045] Sponge-like or foam-like elements may not include cutting lines. Sponge-like or foam-like elements may include a single linear cutting line. Sponge-like or foam-like elements may include two straight cutting lines. Sponge-like or foam-like elements may include two perpendicular straight cutting lines. The two cutting lines may intersect each other. Sponge-like or foam-like elements may include multiple straight lines. Sponge-like or foam-like elements may include multiple straight lines intersecting each other at the same or different angles, thus forming an asterisk-shaped shape.

[0046] One or more cutting lines may be provided such that they do not protrude completely through the sponge-like or foam-like element. One or more cutting lines may be provided such that, when the sponge-like or foam-like element is installed in an inhaler article, it does not protrude completely through the sponge-like or foam-like element in a direction parallel to the longitudinal axis of the inhaler article.

[0047] One or more cutting lines can be provided by pre-cutting into sections of the sheet-like precursor of the sponge or foam element. Pre-cutting can be performed before shaping the precursor of the sponge or foam element into its final form to obtain the final sponge or foam element.

[0048] For example, the sponge-like or foam-like element can have a cylindrical shape. The cylindrical shape can be configured to fit tightly into or onto a tubular body. The cylindrical shape can also be configured to have an outer diameter exceeding the inner diameter of the tubular body. Therefore, the sponge-like or foam-like element can be compressed when inserted into the tubular body. This compression can improve the adhesion of the sponge-like or foam-like element within the tubular body.

[0049] The sponge-like or foam-like element may initially be configured as a sheet or strip of material, which is then wound around the inner cylindrical wall of the tubular body. The sheet or strip of material may include one or more pre-cuts along its length. Each pre-cut may be configured as a cutting line extending in a direction perpendicular to the width of the sheet or strip. The cutting line may be configured not to completely penetrate the width of the sheet or strip, such that the sheet or strip is not cut into multiple pieces.

[0050] For example, the sheet or strip of material may include a plurality of pre-cuts arranged along the length of the strip or sheet such that once the sheet or strip is rolled up along its length and then inserted into a tubular body, it forms a star-shaped cut line.

[0051] Sponge-like or foam-like elements can be manufactured by providing a precursor of a sponge-like or foam-like element in the form of a sheet or strip made of a sponge-like or foam-like material. Optionally, one or more pre-cuts can be cut into the sheet or strip at different locations along its length. Optional pre-cuts are provided such that they do not extend completely across the width of the sheet or strip, allowing the sheet or strip to remain intact. The sheet or strip optionally including the pre-cuts is then rolled into a cylindrical form along its length. Thus, a final resealable retaining element in the form of a cylindrical sponge-like or foam-like element is provided, which optionally includes one or more cut lines, such as multiple cut lines in an asterisk shape.

[0052] The sponge-like or foam-like element may have one or more cut lines, or no cut lines at all. When no cut lines are present, the elasticity of the material alone allows the inhaler article to be easily and conveniently inserted into the retainer and subsequently return to its original shape when the article is removed from the retainer. The sponge-like or foam-like element may be any color, such as white.

[0053] Sponge-like or foam-like components can be configured as single components. Sponge-like or foam-like components can be configured as integral components. Sponge-like or foam-like components can be configured as multi-layered thin sponges or foams.

[0054] The sponge-like or foam-like element can be provided in dry form. The sponge-like or foam-like element can also be provided in wet form, for example, having a moisture content of at least 1% by weight, optionally at least 2% by weight, optionally at least 5% by weight, optionally at least 10% by weight. Providing a wet sponge-like or foam-like element improves its ability to retain powder, particularly dry powder, released from the capsule after use.

[0055] The resealable retention element can be configured as a membrane. The membrane can be formed from a film-forming material. The film-forming material can be a water-based binder. The water-based binder can contain an acrylic copolymer. The water-based binder can be crosslinkable by UV (ultraviolet) light. The water-based binder can be those available from the Swiss company "Archroma" under the trade name "Appretan®". "Appretan®" is a membrane containing natural materials, which can be renewable.

[0056] A resealable retention element configured as a membrane can be used in inhaler articles comprising a tubular body and a flanged front bar. A resealable retention element configured as a membrane can be used in inhaler articles comprising a coiled distal end. A resealable retention element configured as a membrane can be used in inhaler articles comprising an open tubular body.

[0057] The resealable trapping element configured as a membrane can be substantially transparent. As used herein, the term "substantially transparent" means that an object has at least 80%, preferably at least 85%, more preferably at least 90%, and even more preferably at least 95% transparency to visible light in the range of about 400 nanometers to about 700 nanometers.

[0058] The resealable retention element, configured as a membrane, may have a thickness ranging from 1 micrometer to 5000 micrometers, preferably from 10 micrometers to 2000 micrometers. When the resealable retention element is installed in an inhaler article, this thickness can be measured in a direction parallel to the longitudinal axis of the inhaler article.

[0059] The film-forming material can be a liquid solution. The liquid solution can be applied to flanged or coiled tubes or to an open tubular body. For example, the liquid solution can be applied manually using a paintbrush or by dipping the tip of a rod into the solution. Alternatively, the liquid solution can be applied by spraying.

[0060] Once applied, the liquid solution typically requires 5 to 30 minutes to dry and cure, depending on the specific solution and environmental conditions. The drying process can be accelerated. For example, drying time can be shortened by incorporating a drying step. The drying step may include guiding the inhaler article into a drying chamber. For example, a water-based adhesive that can be crosslinked by UV light can be used, and the drying step can be accelerated by using a UV lamp to speed up curing and drying. This can allow curing time to be reduced to a few seconds. By reducing drying time, manufacturing speed can be increased. This, in turn, can reduce manufacturing costs.

[0061] After drying, the resealable retention element configured as a membrane can be substantially transparent. After drying, the thickness of the resealable retention element configured as a membrane can be in the range of 1 micrometer to 5000 micrometers, preferably 10 micrometers to 2000 micrometers.

[0062] The dried layer forming the film can remain a sealed layer in the final inhaler article. The sealed layer can only be perforated during insertion of the inhaler article into the retainer by means of the retainer's piercing device. The dried layer can be cut or perforated in the final inhaler article before use, for example, by cutting it in the middle. This facilitates insertion of the inhaler article into the retainer.

[0063] According to embodiments of the present invention, an inhaler system is provided, comprising an inhaler article as described herein, and a retainer. The retainer may include a retainer cavity configured to receive at least a distal portion of the inhaler article.

[0064] The resealable retention element of an inhaler can be configured to form an interference fit with the corresponding surface of the retainer. This design ensures a secure connection between the resealable retention element and the retainer. The interference fit increases stability, thus contributing to the overall functionality and reliability of the inhaler system.

[0065] The retainer may include a puncture device arranged to puncture a cavity of the inhaler article when it is received in the retainer cavity. The puncture device may be arranged to puncture a capsule included in the cavity of the inhaler article. Upon puncture, the capsule can open, and an aerosol-forming matrix (e.g., dry powder) can be released and entrained by an airflow through the article.

[0066] The puncture device allows for seamless integration and activation of the inhaler article within the retainer. The puncture device enhances user convenience by automating the process of preparing the inhaler article for use during insertion into the retainer cavity.

[0067] As used herein, the terms “tubular,” “tubular unit,” “tubular component,” “tubular element,” “tubular body,” and “tubular shape” refer to a three-dimensional object and three-dimensional geometry, including a bottom base, a top base, and sidewalls defining a hollow interior, with the sidewalls arranged between the bottom and top bases. The sidewalls extend along the longitudinal axis of the tubular body between the bottom and top bases. The longitudinal axis may be perpendicular to one or both of the bottom and top bases.

[0068] The bottom base of the tubular body lies within a bottom base plane. The top base of the tubular body lies within a top base plane. One or both of the bottom and top bases may have a circular cross-sectional shape. One or both of the bottom and top bases may have a non-circular cross-sectional shape, such as elliptical, stadium-shaped, or rectangular. One or both of the bottom and top bases may be at least partially open to provide an internal hollow passageway within the tubular body.

[0069] The tubular body can have the shape of a perfectly circular hollow cylinder. The tubular body can also have the shape of a non-circular hollow cylinder, such as an elliptical hollow cylinder or a stadium-shaped hollow cylinder. The tubular body can also have the shape of a hollow cuboid.

[0070] The longitudinal axis of the tubular body can be arranged parallel to the longitudinal axis of the inhaler article. The longitudinal central axis of the tubular body can coincide with the longitudinal central axis of the inhaler article.

[0071] As used herein, the term "resealable" refers to the ability to reseal or close after being opened. In other words, a resealable retrieval element can be reliably closed once or multiple times after being opened. This maintains the integrity of its contents and prevents leakage or exposure to the external environment.

[0072] As used herein, the term "fluidly isolated" refers to a state in which substances (typically fluids such as liquids or gases) are effectively separated or kept apart from each other, thereby preventing or reducing their interaction or exchange. When two components are fluidly isolated, there are barriers or mechanisms that prevent or reduce the flow or transfer of matter between them, thereby maintaining a clear boundary. As used herein, the term "fluidly isolated" can further refer to a state in which a barrier or mechanism between two components prevents or reduces the migration of powder particles between the two components. The particle size of the powder can include particle sizes in the nanometer and micrometer ranges, or both.

[0073] According to an embodiment of the present invention, an inhaler article is provided. The inhaler article includes a tubular body. The tubular body includes an internal airflow passage extending between an oral end and a distal end of the tubular body. The inhaler article includes a cavity for receiving an aerosol-forming matrix. The cavity is disposed within the tubular body between the oral end and the distal end. The inhaler article includes a resealable retention element disposed at a location distal to the cavity. The resealable retention element is configured to be switchable between an open position and a closed position.

[0074] In the closed position, the portion of the airflow channel between the distal end of the tubular body and the cavity can be closed. This closure reduces or prevents particle migration between the distal end of the tubular body and the cavity. It also reduces or prevents leakage of particles from the cavity from the distal end of the tubular body. In the closed position, the cross-sectional area of ​​the portion of the airflow channel between the distal end of the tubular body and the cavity can be smaller compared to the open position.

[0075] In the open position, the portion of the airflow passage between the distal end of the tubular body and the cavity is open. In the open position, the distal end of the tubular body can be fluidly connected to the cavity.

[0076] In the closed position, compared to the open position, particle migration from the cavity to the distal end of the tubular body can be prevented or reduced. In the closed position, the distal end of the tubular body can be fluidly isolated from the cavity.

[0077] According to embodiments of the present invention, an inhaler article is provided. The inhaler article includes a tubular body. The tubular body includes an internal airflow passage extending between an oral end and a distal end of the tubular body. The inhaler article includes a cavity for receiving an aerosol-forming matrix. The cavity is disposed within the tubular body between the oral end and the distal end. The inhaler article includes a resealable retention element disposed at a location distal to the cavity. The resealable retention element is configured to be switchable between an open position and a closed position. The inhaler article is configured such that, in the closed position, the cross-sectional area of ​​the portion of the airflow passage between the distal end of the tubular body and the cavity is smaller than that in the open position. The inhaler article may be configured such that the cross-section of the airflow passage between the distal end of the tubular body and the cavity is open in the open position and closed or blocked in the closed position.

[0078] The size and shape of the inhaler body may resemble a smoking product or cigarette. The inhaler body may have an elongated body extending along the longitudinal axis of the inhaler product. The inhaler body may have a generally uniform outer diameter along the length of the elongated body. The inhaler body may have a circular cross-section that is uniform along the length of the elongated body. The inhaler body may have an outer diameter ranging from about 6 mm to about 10 mm, or from about 7 mm to about 10 mm, or from about 7 mm to about 9 mm, or from about 7 mm to about 8 mm, or about 7.2 mm. The length of the inhaler body (along the longitudinal axis) may range from about 40 mm to about 80 mm, or from about 40 mm to about 70 mm, or from about 40 mm to about 50 mm, or about 45 mm.

[0079] The inhaler body may include a tubular body.

[0080] The inhaler article may have an open distal or upstream end defined by a tubular element defining a central passage. The open central passage may define a cylindrical opening extending from the capsule cavity to the open distal or upstream end of the inhaler article. The length of the open tubular element defining the open central passage may range from about 3 mm to about 12 mm, or from about 3 mm to about 7 mm, or from about 4 mm to about 6 mm, or about 5 mm.

[0081] The open tubular element defining the open central pathway can be formed of a cellulose material. Alternatively, it can be formed of cellulose acetate. Preferably, the open tubular element is formed of a biodegradable material. The thickness of the open tubular element defining the open central pathway can range from about 0.5 mm to about 1.5 mm or from about 0.5 mm to about 1 mm. The open tubular element can be a tubular body, and the open distal end can be at least partially closed in the closed position by a resealable retention element.

[0082] The inhaler article may include a filter element. The filter element may be located downstream of the capsule. The filter element located downstream of the capsule may extend from the capsule to the mouthpiece end of the inhaler article. The length of the filter element may be in the range of about 10 mm to about 30 mm, preferably about 15 mm to about 25 mm, and more preferably about 20 mm to about 22 mm.

[0083] The cavity may define a cylindrical space configured to accommodate a capsule (e.g., the capsule may have an oblong or circular cross-section). The cavity may have a substantially uniform or consistent diameter along its length. The cavity may have a fixed cavity length. The cavity has an inner diameter orthogonal to its longitudinal axis, and the capsule has an outer diameter. The cavity may be sized to accommodate an oblong capsule. The cavity may have a substantially cylindrical or cylindrical cross-section along its length. The cavity may have a uniform inner diameter. The capsule may have an outer diameter that is approximately 80% to approximately 95% of the inner diameter of the cavity. The configuration of the cavity relative to the capsule may facilitate limited movement of the capsule during activation or puncture. The cavity may be defined by an open tubular element. The open tubular element may be connected between the open tubular element and the filter element at the distal end of the inhaler article, and aligned adjacent to both the open tubular element and the filter element. These elements may be connected using packaging. The open tubular element defining the cavity may be formed of a biodegradable material, such as cardboard or paperboard.

[0084] The cavity-to-sac configuration facilitates stable rotation of the sac within the cavity. During inhalation, the longitudinal axis of the sac can rotate stably coaxially with the longitudinal axis of the inhaler body. The cavity-to-sac configuration also facilitates a certain degree of wobbling rotation of the sac within the cavity.

[0085] Stable rotation means that the longitudinal axis of the inhaler body is substantially parallel to or coaxial with the rotation axis of the capsule. Stable rotation can also mean that the rotating capsule does not travel. Preferably, the longitudinal axis of the inhaler body may be substantially coaxial with the rotation axis of the capsule. Stable rotation of the capsule can provide a uniform entrainment of a portion of the nicotine particles from the capsule during two or more, five or more, or ten or more "inhalations" or breaths by the user.

[0086] Before consumption, the capsule may be sealed within the inhaler article. The inhaler article may be contained within a sealed or airtight container or bag. The inhaler article may include one or more peelable or removable seals to cover one or more air inlet passages or air outlets or mouthpieces of the inhaler article.

[0087] The capsule can rotate about its longitudinal or central axis as airflow passes through the inhaler article. The capsule can be formed of an airtight material that can be punctured or burst by a puncture element, which can be alone or in combination with the inhaler. The capsule can be formed of a metal or polymer material that serves to keep the capsule from contamination and can be punctured or burst by the puncture element before the nicotine particles within the capsule are consumed. The capsule can be formed of a polymer material. The polymer material can be hydroxypropyl methylcellulose (HPMC). The capsule can be a size 1 through 4, or a size 3 capsule.

[0088] Capsules can be nicotine-free. Capsules can contain nicotine.

[0089] The capsule may contain nicotine particles (also known as "nicotine powder" or "nicotine particles") containing nicotine, and optionally particles containing flavoring (also known as "flavoring particles"). The capsule may contain a predetermined amount of nicotine particles and optional flavoring particles. The capsule may contain enough nicotine particles to provide at least 2 inhalations or "puffs," or at least about 5 inhalations or "puffs," or at least about 10 inhalations or "puffs." The capsule may contain enough nicotine particles to provide about 5 to about 50 inhalations or "puffs," or about 10 to about 30 inhalations or "puffs." Each inhalation or "puff" delivers about 0.1 mg to about 3 mg of nicotine particles to the user's lungs, or about 0.2 mg to about 2 mg of nicotine particles to the user's lungs, or about 1 mg of nicotine particles to the user's lungs.

[0090] Depending on the specific formulation used, nicotine particles can have any useful concentration of nicotine. Nicotine particles can have at least about 1% wt of nicotine up to about 30% wt of nicotine, or about 2% wt to about 25% wt of nicotine, or about 3% wt to about 20% wt of nicotine, or about 4% wt to about 15% wt of nicotine, or about 5% wt to about 13% wt of nicotine. Preferably, each inhalation or "puff" delivers about 50 to about 150 micrograms of nicotine to the user's lungs.

[0091] The capsule may hold or contain at least about 5 mg of nicotine particles or at least about 10 mg of nicotine particles. The capsule may hold or contain less than about 900 mg of nicotine particles, or less than about 300 mg of nicotine particles, or less than 150 mg of nicotine particles. The capsule may hold or contain about 5 mg to about 300 mg of nicotine particles or about 10 mg to about 200 mg of nicotine particles.

[0092] When flavoring particles are mixed or combined with nicotine particles within the capsule, the flavoring particles can provide the desired amount of flavoring to the user with each inhalation or "puff".

[0093] Nicotine particles can have any useful particle size distribution for preferential delivery to the user's lungs upon inhalation. Encapsulations may include particles other than nicotine particles. Nicotine particles and other particles can form a powder system.

[0094] The capsule may hold or contain at least about 5 mg of dry powder (also referred to as a powder system) or at least about 10 mg of dry powder. The capsule may hold or contain less than about 900 mg of dry powder, or less than about 300 mg of dry powder, or less than about 150 mg of dry powder. The capsule may hold or contain about 5 mg to about 300 mg of dry powder, or about 10 mg to about 200 mg of dry powder, or about 25 mg to about 10 mg of dry powder. The dry powder or powder system may have a powder system comprising at least about 40% by weight, or at least about 60% by weight, or at least about 80% by weight of nicotine particles with a particle size of about 5 micrometers or less, or in the range of about 1 micrometer to about 5 micrometers. The mass median aerodynamic diameter of the nicotine-containing particles may be about 5 micrometers or less, or in the range of about 0.5 micrometers to about 4 micrometers, or in the range of about 1 micrometer to about 3 micrometers, or in the range of about 1.5 micrometers to about 2.5 micrometers. Preferably, the mass median aerodynamic diameter is measured using a cascade impactor. The mass median aerodynamic diameter of the spice-containing particles can be about 20 micrometers or greater, or about 50 micrometers or greater, or in the range of about 50 to about 200 micrometers, or about 50 to about 150 micrometers. Preferably, the mass median aerodynamic diameter is measured using a cascaded impactor.

[0095] The dry powder may have an average diameter of about 60 micrometers or less, or in the range of about 1 micrometer to about 40 micrometers, or in the range of about 1.5 micrometers to about 25 micrometers. The average diameter refers to the average diameter per unit mass, and is preferably measured by laser diffraction, laser diffusion, or electron microscopy.

[0096] The nicotine or nicotine particles in the powder system can be pharmaceutically acceptable free nicotine, nicotine salts, or nicotine hydrates. Effective nicotine salts or nicotine hydrates include, for example, nicotine pyruvate, nicotine citrate, nicotine aspartate, nicotine lactate, nicotine bitartrate, nicotine salicylate, nicotine fumarate, nicotine monopyruvate, nicotine glutamate, or nicotine hydrochloride. Compounds that combine with nicotine to form salts or hydrates can be selected based on their expected pharmacological effects.

[0097] Preferably, the nicotine particles comprise an amino acid. Preferably, the amino acid can be leucine, such as L-leucine. Providing the nicotine-containing particles with an amino acid such as L-leucine can reduce the adhesive force of the nicotine-containing particles and can reduce the attraction between nicotine particles, thus reducing the agglomeration of nicotine particles. Similarly, the adhesive force with the flavor-containing particles can also be reduced, thus also reducing the agglomeration of nicotine particles with flavor particles. Therefore, even when nicotine particles and flavor particles are combined, the powder system described herein can be a free-flowing material and each powder component has a stable relative particle size. Preferably, the nicotine can be a surface-modified nicotine salt, wherein the nicotine salt particles comprise coated or composite particles. A preferred coated or composite material can be L-leucine. A particularly effective nicotine particle can be a nicotine bitartrate bound with L-leucine.

[0098] Powder systems may include groups of flavor particles. Flavor particles may have any effective particle size distribution for selective delivery of inhalation into the user's mouth or buccal cavity.

[0099] The powder system may have at least about 40% by weight, or at least about 60% by weight, or at least about 80% by weight of a fragrance particle group comprising particles having a particle size of about 20 micrometers or larger. The powder system may have at least about 40% by weight, or at least about 60% by weight, or at least about 80% by weight of a fragrance particle group comprising particles having a particle size of about 50 micrometers or larger. The powder system may have at least about 40% by weight, or at least about 60% by weight, or at least about 80% by weight of a fragrance particle group comprising particles with a particle size in the range of about 50 micrometers to about 150 micrometers.

[0100] The fragrance-containing particles may contain compounds for reducing adhesion or surface energy and the resulting agglomeration. The fragrance particles can be surface-modified using adhesion-reducing compounds to form coated fragrance particles. A preferred adhesion-reducing compound is magnesium stearate. Providing the fragrance particles with adhesion-reducing compounds such as magnesium stearate, especially coating the fragrance particles, can reduce the adhesion of the fragrance-containing particles and the attraction between the fragrance particles, and thus reduce the agglomeration of the fragrance particles. Therefore, the agglomeration of the fragrance particles with nicotine particles can also be reduced. Thus, even when nicotine particles and fragrance particles are combined, the powder system described herein can have a stable relative particle size between the nicotine-containing particles and the fragrance-containing particles. The powder system is preferably free-flowing.

[0101] Because the active particles may be too small to be affected by the simple airflow through the inhaler, conventional formulations for dry powder inhalation include carrier particles to increase the fluidity of the active particles. Powder systems may include carrier particles. These carrier particles can be sugars such as lactose or mannitol, and can have a particle size greater than about 50 micrometers. By acting as a diluent or loosening agent in the formulation, carrier particles can be used to improve dose uniformity. Powder systems used in conjunction with the nicotine powder delivery systems described herein may be carrier-free or substantially free of sugars such as lactose or mannitol. The absence of a carrier or the substantial absence of sugars such as lactose or mannitol allows nicotine to be inhaled and delivered to the user's lungs at an inhalation rate or airflow rate similar to that of typical smoking.

[0102] Nicotine particles and flavorings can be combined in a single capsule. As described above, the nicotine particles and flavorings can each have reduced adhesive forces, resulting in a stable granular formulation in which the particle size of each component remains substantially unchanged upon combination. Alternatively, a powder system may comprise nicotine particles contained in a single capsule and flavoring particles contained in a second capsule.

[0103] Nicotine particles and flavoring particles can be combined in any effective relative amount such that the flavoring particles are perceptible to the user when consumed together with the nicotine particles. Preferably, the nicotine particles and flavoring particles form at least about 90% wt, or at least about 95% wt, or at least about 99% wt, or 10% wt of the total weight of the powder system. Compared to conventional dry powder inhalers, the inhaler and inhaler system may be less complex and have a simplified airflow path. Advantageously, the rotation of the capsule within the inhaler body aerosolizes the nicotine particles or powder system and can help maintain a free-flowing powder. Therefore, the inhaler article may not require the higher inhalation rates typically utilized by conventional inhalers to deliver the nicotine particles described above deep into the lungs.

[0104] Inhaler articles can use flow rates below about 5 L / min, or below about 3 L / min, or below about 2 L / min, or about 1.6 L / min. Preferably, the flow rate can be in the range of about 1 L / min to about 3 L / min, or about 1.5 L / min to about 2.5 L / min. Preferably, the inhalation rate or flow rate can be similar to the inhalation rate or flow rate of Health Canada smoking, i.e., about 1.6 L / min.

[0105] Users can use the inhaler system just like smoking a regular cigarette or vaping. This type of smoking or vaping is characterized by two steps: first, during which a small amount containing the user's desired full amount of nicotine is inhaled into the mouth; then, in the second step, during which this small amount of nicotine-containing aerosol is further diluted with fresh air and inhaled more deeply into the lungs. Both steps are user-controlled. During the first inhalation step, the user determines the amount of nicotine to be inhaled. During the second step, the user determines the amount used to dilute the first amount for deeper inhalation into the lungs, maximizing the concentration of the active agent delivered to the respiratory epithelial surface. This smoking mechanism is sometimes referred to as "inhale-exhale."

[0106] The median aerodynamic diameter of the pharmaceutically active particles may be about 5 micrometers or less, or in the range of about 0.5 micrometers to about 4 micrometers, or in the range of about 1 micrometer to about 3 micrometers.

[0107] The capsule may also contain a second group of spice particles with a median aerodynamic diameter of about 20 micrometers or more, or about 50 micrometers or more, or in the range of about 50 to about 200 micrometers, or about 50 to about 150 micrometers.

[0108] The term "nicotine" refers to nicotine and nicotine derivatives, such as free nicotine base and nicotine salts.

[0109] The terms “flavoring” or “spice” refer to sensory compounds, compositions or materials that alter or are intended to alter the taste or aroma properties of nicotine during its consumption or inhalation.

[0110] The terms “upstream” and “downstream” refer to the relative positions of the components of the retainer, inhaler article, and inhaler system with respect to the direction of the inhalation airflow as the inhaled airflow passes through the retainer body, inhaler article, and inhaler system.

[0111] The terms "proximal" and "distal" are used to describe the relative positions of components or portions of components in a retainer, inhaler article, or system. A retainer or element forming a retainer (such as a sleeve) according to the invention has: a proximal end that receives the inhaler article in use; and an opposing distal end, which may be a closed end or an end having a portion closer to the proximal end of the retainer. An inhaler article according to the invention has a proximal end. In use, nicotine particles exit the proximal end of the inhaler article for delivery to the user. The inhaler article has a distal end opposite the proximal end. The proximal end of the inhaler article may also be referred to as the oral end.

[0112] The retainer described herein for inhaler articles can be combined with an inhaler article containing a sac to activate the inhaler article by puncturing the sac, thereby providing reliable activation of the sac within the inhaler article (by puncturing the sac with the retainer's puncturing element) and releasing the particles contained within the sac, and enabling the article to deliver the particles to the user. The retainer is separate from the inhaler article, but the user can utilize both the inhaler article and the retainer to simultaneously consume the particles released within the inhaler article. Multiple such inhaler articles can be combined with the retainer to form a system or kit. A single retainer can be used on 10 or more, or 25 or more, or 50 or more, or 10 or more inhaler articles to activate (puncture or pierce) the sac contained within each inhaler article, and to provide reliable activation and optional visual indication (marking) for each inhaler article.

[0113] The retainer described herein for inhaler articles can be combined with an inhaler article containing a sac to activate the inhaler article by puncturing the sac, thereby providing reliable activation of the sac within the inhaler article (by puncturing the sac with the retainer's puncturing element) and releasing the particles contained within the sac, and enabling the article to deliver the particles to the user. The retainer is separate from the inhaler article, but the user can utilize both the inhaler article and the retainer to simultaneously consume the particles released within the inhaler article. Multiple such inhaler articles can be combined with the retainer to form a system or kit. A single retainer can be used on 10 or more, or 25 or more, or 50 or more, or 10 or more inhaler articles to activate (puncture or pierce) the sac contained within each inhaler article, and to provide reliable activation and optional visual indication (marking) for each inhaler article.

[0114] An inhaler system includes an inhaler article and a retainer for the inhaler article as described herein. A retainer sleeve holds the inhaler article received in a sleeve cavity. A bladder may be disposed within the body of the inhaler article. The inhaler article may include a body extending along the longitudinal axis of the inhaler from the mouthpiece end to a distal end. A bladder cavity may be defined within the body, the body being defined downstream by a filter element and upstream by a tubular element defining a central passage. The central passage may form an air inlet orifice extending from the distal end of the body toward the bladder cavity. A bladder may be disposed within the bladder cavity, wherein the central passage may have a smaller diameter than the bladder. Therefore, the bladder does not pass through the central passage and is held within the bladder cavity.

[0115] The following is a non-exhaustive list of non-limiting examples. Any one or more features of these examples may be combined with any one or more features of another example, embodiment, or aspect described herein.

[0116] Example 1: An inhaler product comprising:

[0117] A tubular body, the tubular body including an internal airflow channel extending between the inlet end of the tubular body and the distal end of the tubular body;

[0118] A cavity for receiving an aerosol-forming matrix, the cavity being disposed within the tubular body between the open end and the distal end; and

[0119] A resealable retention element is disposed at a position distal to the cavity.

[0120] The resealable trapping element is configured to be switchable between an open position and a closed position.

[0121] In the open position, the distal end of the tubular body is fluidly connected to the cavity, and

[0122] In the closed position, the distal end of the tubular body is fluidly isolated from the cavity.

[0123] Example 2: An inhaler article according to Example 1, wherein the resealable trapping element is configured to switch between the open position and the closed position based on the presence or absence of a pressure difference generated in the internal airflow passage between the inlet and distal ends of the tubular body.

[0124] Example 3: According to the inhaler article of Example 2, wherein the resealable retention element is configured to move toward the open position when a negative pressure is applied at the mouth end, and wherein the resealable retention element is configured to move back toward the closed position when the negative pressure is not present.

[0125] Example 4: An inhaler article according to any of the foregoing examples, wherein the resealable retention element includes a flexible portion that is movable between a relaxed configuration when the resealable retention element is in the closed position and a tensioned configuration when the resealable retention element is in the open position.

[0126] Example 5: An inhaler article according to Example 4, wherein the resealable retention element is configured as a disc, the disc including one or more weakening lines to provide one or more flexible flaps, and wherein the flexible portion is provided by the one or more flexible flaps.

[0127] Example 6: Inhaler article according to Example 5, wherein one or more weakening lines are perforated lines or cut lines.

[0128] Example 7: An inhaler article according to Example 5 or Example 6, wherein the disc includes two orthogonally arranged weakening lines to provide four flexible flaps of equal size.

[0129] Example 8: An inhaler article according to any one of Examples 1 to 3, wherein the resealable trapping element includes a one-way valve, optionally wherein the one-way valve includes a valve disc movable between the closed position and the open position.

[0130] Example 9: An inhaler article according to any of the preceding examples, comprising a flanged front bar disposed at the distal end of the tubular body, wherein the distal end of the tubular body is at least partially closed by the flanged front bar.

[0131] Example 10: An inhaler article according to Example 9, wherein the resealable retention element is attached to the flanged front bar, preferably wherein the resealable retention element is attached to the inner side of the flanged front bar.

[0132] Example 11: An inhaler article according to Example 9, wherein the resealable retention element is attached to the outer side of the flanged front bar.

[0133] Example 12: An inhaler article according to any one of Examples 1 to 9, wherein the resealable retention element is attached to the distal end of the tubular body via a connecting package.

[0134] Example 13: The inhaler article according to Example 12, wherein the connecting packaging is a paper outer packaging.

[0135] Example 14: An inhaler article according to any of the preceding examples, including a retention rod, wherein the retention rod is positioned between the cavity and the proximal end.

[0136] Example 15: An inhaler article according to Example 14, wherein the retention rod comprises a bioplastic.

[0137] Example 16: An inhaler article according to any of the foregoing examples, wherein the resealable trapping element comprises at least one of tobacco, cotton, paper, rayon, cork, latex, starch-based plastic material and silicone.

[0138] Example 17: An inhaler article according to any of the preceding examples, wherein the tubular body comprises cardboard.

[0139] Example 18: An inhaler article according to any of the foregoing examples, wherein the cavity is a capsule cavity configured to receive a capsule comprising the aerosol forming matrix.

[0140] Example 19: An inhaler article according to Example 18, wherein the capsule is a puncturable capsule comprising pharmaceutically active particles in the form of dry powder, optionally wherein the pharmaceutically active particles contain nicotine.

[0141] Example 20: An inhaler article according to any of the foregoing examples, wherein the resealable retention element is a sponge-like or foam-like element as described herein.

[0142] Example 21: An inhaler article according to any one of Examples E1 to E19, wherein the resealable retention element is configured as a membrane as described herein.

[0143] Example 22: An inhaler system comprising an inhaler article according to any of the preceding examples, and a retainer, wherein the retainer includes a retainer cavity configured to receive at least a distal portion of the inhaler article.

[0144] Example 23: An inhaler system according to Example 22, wherein the resealable retention element is configured to form an interference fit with the corresponding surface of the retainer.

[0145] Example 24: An inhaler system according to Example 22 or 23, wherein the retainer includes a piercing device arranged to pierce into the cavity of the inhaler article when the inhaler article is received in the retainer cavity.

[0146] The features described with respect to one embodiment can also be applied to other embodiments of the invention. Attached Figure Description

[0147] The invention will be further described by way of example only with reference to the accompanying drawings, in which:

[0148] Figure 1 An inhaler product is shown;

[0149] Figure 2 a and 2b illustrate resealable trapping elements;

[0150] Figure 3 a shows a resealable trap element;

[0151] Figure 3 b and 3c show inhaler products;

[0152] Figure 4 An inhaler system is shown;

[0153] Figure 5 The inhaler product after use is shown;

[0154] Figure 6 a and 6b show inhaler products;

[0155] Figure 7 a shows a resealable trap element;

[0156] Figure 7b illustrates a method for manufacturing a resealable retention element; and

[0157] Figure 8 a and 8b show inhaler products. Detailed Implementation

[0158] Figure 1 A cross-sectional view of an inhaler article 10 is shown. The inhaler article 10 includes a tubular body 12 with an internal airflow passage extending between an oral end 14 of the tubular body 12 and a distal end of the tubular body 12 including a flanged front bar 16. The inhaler article 10 includes a cavity 18 for receiving an aerosol-forming matrix. The cavity 18 is disposed within the tubular body 12 between the oral end 14 and the distal end including the flanged front bar 16. The inhaler article 10 includes a retention rod 20. The retention rod 20 is positioned between the cavity 18 and the proximal end including the oral end 14. The inhaler article 10 includes an outer packaging 38, such as a paper packaging. The outer packaging 38 may allow for the provision of user information printed thereon. The inhaler article 10 includes a puncturable capsule 22 containing the aerosol-forming matrix. The capsule 22 may include the aerosol-forming matrix in the form of a dry powder. The capsule 22 is positioned within the cavity 18 formed by the tubular body 12. The cavity 18 is a capsule cavity. The cavity 18 is at least partially sealed at both the distal and proximal ends by the intercepting rod 20 and the flanged front rod 16.

[0159] The inhaler article 10 also includes a resealable retention element 24 positioned below the flanged front bar 16. The resealable retention element 24 is positioned within the cavity 18. The outer edge of the resealable retention element 24 may be attached, for example, via adhesive to the inner surface of the tubular body 12. The resealable retention element 24 is configured to be switchable between an open position and a closed position. In the closed position, as shown, the distal end of the tubular body 12 is fluidly isolated from the cavity 18. Therefore, the inhaler article 10 can reduce or prevent leakage of material from the distal end 16 within the cavity 18.

[0160] Figure 2 a and 2b show suitable for use Figure 1 An embodiment of the resealable trapping element 24 in the inhaler article 10.

[0161] exist Figure 2 Figure a shows a top view of a resealable trap element 24 in the form of a disc. The disc is shaped as a flattened right cylinder. The disc includes weakening lines 26. The weakening lines 26 may be perforated lines or cut lines.

[0162] exist Figure 2 b shows the presentation Figure 2A side view of a disc-shaped resealable trap element 24. Suitable dimensions associated with the disc-shaped resealable trap element 24 are shown. The diameter (A) of the disc-shaped resealable trap element 24 can be between 5 mm and 13 mm, preferably between 6 mm and 11 mm, more preferably between 7 mm and 9 mm. The height (B) of the disc-shaped resealable trap element 24 can be between 0.1 mm and 4 mm, preferably between 0.1 mm and 3 mm, more preferably between 0.1 mm and 2 mm. A weakening line 26 is configured to allow the disc to open, and thus allow airflow through the cavity 18 during use. For example, the weakening line 26 can be applied to the resealable trap element 24 using a laser perforator, perforating wheel, or needle perforation device, as is used to apply vents in cigarette manufacturing.

[0163] In the illustrated embodiment, Figure 2 The resealable trap element 24 includes two orthogonally arranged weakening lines 26 to provide four equally sized flexible flaps. These flexible flaps together constitute the flexible portion of the resealable trap element 24. By incorporating the weakening lines into these flaps, the trap element can be given the necessary adaptability to its operating modes.

[0164] Figure 3 a again showed Figure 2 a's resealable retention element 24. Figure 3 b shows along as... Figure 3 The cross-section (X) shown in Figure a shows the inhaler article 10 installed in the open position. Figure 2 a and Figure 3 a's resealable trap element 24. Figure 3 As shown in b, in the open position, four equally sized flexible flaps constituting the flexible portion of the resealable retention element 24 bend open toward the proximal end of the inhaler article 10. This bending to the open position can be caused by negative pressure applied at the mouth end of the article, for example, by the user's suction action. When the user stops suctioning, the flaps can bend back to the closed position, for example, as shown in b. Figure 1 As shown in the image.

[0165] This provides the possibility of opening and sealing the flanged front bar 16. Therefore, the resealable trap element 24 is configured to move toward the open position when a negative pressure is applied at the port 14. The resealable trap element 24 is also configured to move back toward the closed position when no negative pressure is present. This prevents leakage.

[0166] Figure 3 c further illustrates Figure 1The open state of the resealable retention element 24 within the inhaler article 10. As previously detailed, the inhaler article 10 is characterized by a tubular body 12 having an internal air flow channel that extends between the mouth end 14 and the distal end of the retainer band flanged front rod 16. A cavity 18 configured to receive an aerosol-forming substrate is located within this tubular body 12 between the mouth end 14 and the distal end. Additionally, the inhaler article 10 includes a retention rod 20 located between the cavity 18 and the proximal end. The inhaler article 10 includes a paper wrapper 38. Inside the inhaler article 10, a pierceable capsule 22 containing an active substance is positioned within the capsule cavity 18, which is sealed at the proximal and distal ends by the retention rod 20 and the flanged front rod 16, respectively.

[0167] Figure 4 An embodiment of an inhaler system is shown that includes Figure 1 an inhaler article 10, and a retainer 28. The retainer 28 includes a retainer cavity configured to receive the distal portion of the inhaler article 10. The retainer 28 includes piercing means (not shown) for piercing the capsule 22 at the piercing point 30. Additionally, the retainer 28 opens the flanged front rod by folding the flanged front rod 16 inwardly. Further, the retainer 28 opens the resealable retention element 24 by folding four movable flaps inwardly. An interference fit is formed with the corresponding face of the retainer 28. Due to the interference fit, the inhaler article 10 is further retained within the retainer 28 during use. When the user inhales, an air flow 32 is generated. The air flow 32 can be used to rotate the capsule within the cavity 18 and against the retention rod 20. The rotational movement of the capsule can promote the release of powder from the capsule by centrifugal force. This can generate a powder flow 34. The powder flow 34 can then travel through the retention rod 20, through the mouth rod 14 to the powder outlet 36, where the powder flow can be inhaled by the user.

[0168] Figure 5 An inhaler article 10 is shown after being removed from the retainer 28 Figure 4 The resealable retention element 24 has returned to its original position, thereby preventing the powder flow 34 from forming a powder leak 36 outside the inhaler article 10. In this way, powder leakage can be reduced or prevented. This can ensure higher safety and user convenience.

[0169] Figure 6 a shows an inhaler article 10. Different from Figure 1 the inhaler article 10, in Figure 6 an inhaler article 10, the resealable retention element 24 is located outside the capsule cavity 18 and attached to the flanged front rod 16 of the tubular body 12.

[0170] Figure 6 b shows an inhaler article 10. Different from Figure 1The inhaler products are 10 different, in Figure 6 In the inhaler article 10 of b, the resealable retention element 24 is positioned at the end of the open main tube 12, without a front flange. The resealable retention element 24 is formed as a disc. The disc is attached to the appropriate position via an additional connecting package 40. The package facilitates a secure and reliable connection between the element and the tubular body, thereby ensuring proper positioning and functionality of the retention element.

[0171] The additional connecting package 40 may be a paper outer packaging. The additional connecting package 40 provides a practical and readily available means of securing the resealable retention element 24 to the distal end of the tubular body 12. The use of the additional connecting package 40 ensures a functional and user-friendly connection while maintaining an overall aesthetic within the design of the inhaler article 10.

[0172] Figure 7 A top view shows three different resealable trapping elements 24 used in an inhaler article 10 as described herein. Figure 7 The resealable trapping element 24 of a is a sponge-like or foam-like element 24. The sponge-like or foam-like element 24 comprises a sponge-like or foam-like material. The sponge-like or foam-like material can be any type of sponge known to those skilled in the art. For example, polymeric sponges, cellulose-based sponges, synthetic sponges, or any combination thereof. Cellulose-based sponges can advantageously be completely sustainable.

[0173] The density of the sponge-like or foam-like element 24 and the elasticity of its constituent materials can limit the effectiveness of the element in opening and closing within and after removal from the retainer 28. According to a specific embodiment, the thickness of the sponge-like or foam-like element 24 can also be varied to optimize sealing efficiency and effectiveness. For example, reducing the thickness can reduce the force required for insertion, and vice versa.

[0174] The sponge-like or foam-like element 24 may include one or more weakening lines 26.

[0175] The weakening line 26 can be set as a cutting line 26. Various cutting shapes are possible. By changing the cutting shape, the opening and closing behavior of the element in and after being removed from the retainer 28 can be varied. For example, when the number of cutting lines 26 is increased, the force required for insertion can be reduced.

[0176] By changing the cutting shape, the sponge-like or foam-like element 24 can therefore be optimized according to the requirements of a specific embodiment.

[0177] Figure 7A shows an embodiment of a sponge or foam element 24 including one cutting line 26 on the left, an embodiment of a sponge or foam element 24 including two cutting lines 26 in the middle, and an embodiment of a sponge or foam element 24 including three cutting lines 26 on the right.

[0178] The cutting line 26 can be set to any desired shape. For example, as... Figure 7 The middle of a is exemplarily shown as a cross shape with two perpendicular or not perfectly perpendicular straight cutting lines 26. For example, as... Figure 7 A simple linear cutting line 26 is exemplarily shown on the left side of a. For example, as... Figure 7 An example shown on the right side of a is a star-shaped shape comprising multiple straight lines 26 intersecting each other at the same or different angles.

[0179] The cutting line 26 can be configured so that when the resealable retention element 24 is installed in the inhaler article 10, it does not protrude completely through the sponge or foam element 24 in a direction parallel to the longitudinal axis of the inhaler article 10.

[0180] Cutting lines 26 can be provided by pre-cutting into sections of the sheet-like precursor of the sponge or foam element 24 before shaping the precursor of the sponge or foam element 24 into its final shape to obtain the final sponge or foam element 24.

[0181] For example, the sponge-like or foam-like element 24 may have a cylindrical shape. The cylindrical shape may be configured to fit tightly into or onto the tubular body 12. The cylindrical shape may be configured to have a diameter larger than the inner diameter of the tubular body 12. Therefore, the sponge-like or foam-like element 24 can be compressed when inserted into the tubular body 12. This can, for example, improve the adhesion of the sponge-like or foam-like element 24 within the tubular body 12.

[0182] The sponge-like or foam-like element 24 can be configured as a sheet or strip of material rolled up within the cylindrical wall inside the tubular body 12. The material sheet or strip may include one or more pre-cuts all along the strip or sheet. For example, the material sheet or strip may include multiple pre-cuts all along the strip or sheet such that once rolled up and inserted into the tubular body 12, the shape of the cut lines 26 (such as the asterisk shape described above) will be formed. (The following is in conjunction with...) Figure 7 b. Describe a suitable method by example.

[0183] Figure 7 b illustrates a method for manufacturing the resealable trap element 24. Figure 7 The left side of b shows the result of the first step in providing a precursor for a resealable trapping element 24 in the form of a sheet 23 of sponge or foam material. Figure 7The middle of b illustrates the result of an optional subsequent step of providing one or more pre-cuts into sheet 23. The optional pre-cuts do not extend completely through sheet 23, thus keeping sheet 23 intact. Figure 8 The right side of b shows the result of the final step of rolling sheet 23 into a cylindrical shape to obtain a final resealable retaining element 24 in the form of a cylindrical sponge or foam element 24, which optionally includes multiple cut lines 26 in an asterisk shape. For illustrative purposes, lines 25 where opposite ends of the rolled sheet 23 meet are indicated. Lines 25 may be invisible or nearly invisible to the user's eye. Opposite ends may come into contact with each other to provide a tight seal at line 25. Opposite ends may be resilient and may be pressed against each other to provide a tight seal at line 25. Opposite ends may be attached to each other, for example, by applying adhesive.

[0184] The sponge-like or foam-like element 24 may have one or more cutting lines 26, or no cutting lines 26 at all. When the cutting lines 26 are absent, the elasticity of the material alone allows the inhaler article 10 to be easily and conveniently inserted into the retainer 28, and subsequently returns to its original shape when the article 10 is removed from the retainer 28. The sponge-like or foam-like element 24 may be of any color.

[0185] The sponge-like or foam-like element 24 can be configured as a single component. The sponge-like or foam-like element 24 can also be configured as a single, integral component. Alternatively, the sponge-like or foam-like element 24 can be configured as multiple layers of thin sponge or foam.

[0186] For example, the sponge or foam element 24 can be attached to the inhaler rod 10 by gluing, by double-sided adhesive, or by sewing. The sponge or foam element 24 can be attached to the inhaler rod 10 by any mechanical or chemical means known to those skilled in the art suitable for holding the element in a desired position.

[0187] The sponge-like or foam-like element 24 may be provided in dry form. The sponge-like or foam-like element 24 may also be provided in wet form, for example, having a moisture content of at least 1% by weight, optionally at least 2% by weight, optionally at least 5% by weight, optionally at least 10% by weight. Providing a wet sponge-like or foam-like element 24 can improve the retention of powder, particularly dry powder, released from the capsule 22 after use.

[0188] Figure 8A and B show the distal portion of the inhaler article 10 in perspective views. The resealable retention element 24 can be configured as a membrane. The membrane is formed of a film-forming material. The film-forming material can be a water-based binder. The water-based binder can contain an acrylic copolymer. The water-based binder can be crosslinkable by UV (ultraviolet) light. The water-based binder can be from the group of water-based binders available from the Swiss company "Archroma Management GmbH" under the trade name "Appretan®".

[0189] like Figure 8 As shown in Figure a, a resealable retention element 24 comprising a film-forming material can be used in an inhaler article 10 comprising a tubular body 12 and a flanged front bar 16. The resealable retention element 24 comprising a film-forming material can be used in an inhaler article 10 comprising a coiled distal end (not shown). ​ As shown in b, the resealable retention element 24, which includes a film-forming material, can be used in an inhaler article 10 that includes an open tubular body 12.

[0190] The resealable trapping element 24, which includes the film-forming material, can be substantially transparent.

[0191] The thickness of the resealable retention element 24, including the film-forming material, can range from 1 micrometer to 5000 micrometers, preferably from 10 micrometers to 2000 micrometers. When the resealable retention element 24 is installed in the inhaler article 10, this thickness can be measured in a direction parallel to the longitudinal axis of the inhaler article 10.

[0192] The film-forming material can be a liquid solution. The liquid solution can be applied to a flanged or coiled tube or an open tubular body 12. For example, the liquid solution can be applied manually using a paintbrush or by dipping a rod tip into the solution. Alternatively, the liquid solution can be applied by spraying.

[0193] Once applied, the liquid solution typically requires 5 to 30 minutes to dry and cure, depending on the specific solution and environmental conditions. The drying process can be accelerated. For example, drying time can be shortened by incorporating a drying step. The drying step may include guiding the inhaler article into a drying chamber. For example, a water-based adhesive that can be crosslinked by UV light can be used, and the drying step can be accelerated by using a UV lamp to speed up curing and drying. This can allow curing time to be reduced to a few seconds. By reducing drying time, manufacturing speed can be increased. This, in turn, can reduce manufacturing costs.

[0194] After drying, the resealable retention element 24, including the film-forming material, can be substantially transparent. After drying, the thickness of the resealable retention element 24, including the film-forming material, can be in the range of 1 micrometer to 5000 micrometers, preferably 10 micrometers to 2000 micrometers.

[0195] The dry layer may be maintained as a closed layer in the final inhaler article 10. The closed layer may be perforated only during the insertion of the inhaler article 10 into the retainer 28. The dry layer may be cut or perforated in the final inhaler article before use, for example, by cutting it in the middle. This facilitates the insertion of the inhaler article 10 into the retainer 28.

Claims

1. An inhaler article, comprising: A tubular body, the tubular body including an internal airflow channel extending between the inlet end of the tubular body and the distal end of the tubular body; A cavity for receiving an aerosol-forming matrix, the cavity being arranged in the tubular body between the oral end and the distal end; as well as A resealable retention element is disposed at a position distal to the cavity. The resealable trapping element is configured to be switchable between an open position and a closed position. In the open position, the distal end of the tubular body is fluidly connected to the cavity. In the closed position, the distal end of the tubular body is fluidly isolated from the cavity. The resealable retaining element includes a flexible portion that is movable between a relaxed configuration when the resealable retaining element is in the closed position and a tensioned configuration when the resealable retaining element is in the open position. The resealable trapping element is configured as a disc, the disc including one or more weakening lines to provide one or more flexible flaps, and The flexible portion is provided by the one or more flexible flaps.

2. The inhaler article of claim 1, wherein the resealable trapping element is configured to switch between the open position and the closed position based on the presence or absence of a pressure difference generated in the internal airflow passage between the orifice and distal ends of the tubular body.

3. The inhaler article of claim 2, wherein the resealable retention element is configured to move toward the open position when a negative pressure is applied at the mouth end, and wherein the resealable retention element is configured to move back toward the closed position when the negative pressure is absent.

4. The inhaler article according to any one of the preceding claims, wherein the one or more weakening lines are perforated lines or cut lines.

5. The inhaler article according to any one of the preceding claims, wherein the disc comprises two orthogonally arranged weakening lines to provide four flexible flaps of equal size.

6. The inhaler article according to any one of the preceding claims, comprising a flanged front bar disposed at the distal end of the tubular body, wherein the distal end of the tubular body is at least partially closed by the flanged front bar.

7. The inhaler article of claim 6, wherein the resealable retention element is attached to the inner side of the flanged front bar, or The resealable trapping element is attached to the outer side of the flanged front bar.

8. The inhaler article according to any one of claims 1 to 6, wherein the resealable retention element is attached to the distal end of the tubular body via a connecting package.

9. The inhaler article according to any one of the preceding claims, comprising a retention rod, wherein the retention rod is positioned between the cavity and the mouth end.

10. The inhaler article according to any one of the preceding claims, wherein the resealable trapping element comprises at least one of tobacco, cotton, paper, rayon, cork, latex, starch-based plastic material, and silicone.

11. The inhaler article according to any one of the preceding claims, wherein the cavity comprises a capsule, the capsule comprising the aerosol forming matrix.

12. The inhaler article of claim 11, wherein the aerosol forming matrix is ​​provided as pharmaceutically active particles in the form of a dry powder, optionally wherein the pharmaceutically active particles comprise nicotine.

13. An inhaler system comprising an inhaler article according to any one of the preceding claims, and a retainer, wherein the retainer includes a retainer cavity configured to receive at least a distal portion of the inhaler article.

Images